Protalix BioTherapeutics, Inc. (PLX)
Largest Insider Buys in Sector
PLX Stock Price History Chart
PLX Stock Performance
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a …
Insider Activity of Protalix BioTherapeutics, Inc.
Over the last 12 months, insiders at Protalix BioTherapeutics, Inc. have bought $0 and sold $0 worth of Protalix BioTherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Protalix BioTherapeutics, Inc. have bought $167,854 and sold $2.09M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 64,516 shares for transaction amount of $90,484 was made by Bashan Dror (PRESIDENT AND CEO) on 2023‑10‑19.
List of Insider Buy and Sell Transactions, Protalix BioTherapeutics, Inc.
| 2023-10-19 | PRESIDENT AND CEO | 64,516 0.0878% | $1.40 | $90,484 | -13.79% | |||
| 2023-01-03 | director | 110,000 0.1979% | $1.42 | $155,815 | +30.97% | |||
| 2022-04-11 | President and CEO | 68,000 0.1528% | $1.50 | $102,000 | -19.15% | |||
| 2021-06-03 | Sale | 10 percent owner | 857,506 1.9156% | $2.25 | $1.93M | -48.20% | ||
| 2021-06-02 | Sale | 10 percent owner | 61,211 0.1389% | $2.56 | $156,553 | -53.63% | ||
| 2020-04-07 | director | 64,000 0.1994% | $2.43 | $155,264 | +53.33% | |||
| 2017-05-16 | President & CEO | 50,000 0.0383% | $0.81 | $40,500 | -20.48% | |||
| 2016-12-02 | Sale | 10 percent owner | 2.5M 2.5199% | $0.32 | $792,000 | +145.16% | ||
| 2015-12-14 | Vice President & CFO | 10,000 0.01% | $0.78 | $7,800 | -2.56% | |||
| 2015-10-19 | 10 percent owner | 4M 4.0937% | $1.00 | $4M | -18.37% | |||
| 2014-08-13 | Sale | 4.4M 4.4447% | $2.47 | $10.87M | -21.67% | |||
| 2014-08-13 | Sale | 10 percent owner | 4.4M 4.4447% | $2.47 | $10.87M | -21.67% | ||
| 2013-08-15 | Sale | director | 2,330 0.0025% | $5.07 | $11,813 | -14.98% | ||
| 2013-08-14 | Sale | director | 110,000 0.1193% | $5.05 | $555,750 | -14.78% | ||
| 2013-03-12 | Sale | director | 10,000 0.0108% | $5.70 | $57,000 | -12.63% | ||
| 2013-03-11 | Sale | director | 18,300 0.0198% | $5.72 | $104,737 | -12.63% | ||
| 2013-03-08 | Sale | director | 16,898 0.0182% | $5.86 | $99,068 | -14.94% | ||
| 2013-03-07 | Sale | director | 8,435 0.0092% | $5.72 | $48,233 | -12.17% | ||
| 2013-03-06 | Sale | director | 4,700 0.0051% | $5.69 | $26,737 | -11.71% | ||
| 2012-05-02 | Sale | Executive VP, R&D | 300,000 0.3334% | $7.13 | $2.14M | -20.83% |
Insider Historical Profitability
| Camber Capital Management LLC | 10 percent owner | 10775000 14.6333% | $1.77 | 1 | 1 | <0.0001% |
| FROST PHILLIP MD ET AL | 10 percent owner | 7610167 10.3352% | $1.77 | 2 | 25 | +14.01% |
| Shaaltiel Yoseph | Executive VP, R&D | 463754 0.6298% | $1.77 | 4 | 16 | <0.0001% |
| Schwartz Aharon | director | 174000 0.2363% | $1.77 | 2 | 0 | +42.15% |
| Bashan Dror | PRESIDENT AND CEO | 132516 0.18% | $1.77 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $4.17M | 4.51 | 3.31M | -4.26% | -$185,493.40 | <0.0001 | |
| State Street | $1.04M | 1.13 | 826,581 | 0% | +$0 | <0.0001 | |
| Renaissance Technologies | $1.04M | 1.13 | 824,700 | +23.9% | +$200,442.46 | <0.01 | |
| Geode Capital Management | $950,178.00 | 1.03 | 754,110 | +4.08% | +$37,214.08 | <0.0001 | |
| Gsa Capital Partners Llp | $622,000.00 | 0.67 | 493,571 | -9.31% | -$63,850.74 | 0.05 |